GlassScriptPhysician profile
Daniel Alberto Cadena Castillo
NPI 1225269673
$4,535.56
in general payments reported to CMS, 2019-2025
25 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2021: $655 · 2022: $617 · 2023: $623 · 2024: $1,469 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Travel and Lodging: $461 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.30 |
| Travel and Lodging | $460.80 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,928.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $894.89 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $345.70 | 2019-2025 | Mounjaro, Jardiance |
| Amgen INC. | $233.31 | 2019-2024 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.18 | 2023-2024 | Jardiance |
| Abbott Laboratories | $106.22 | 2019-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $97.00 | 2023-2025 | Unithroid |
| Medtronic Minimed, INC. | $92.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $79.36 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $76.65 | 2025 | |
| Sanofi-Aventis U.S. LLC | $65.82 | 2019 | |
| Dexcom, INC. | $59.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.06 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $52.05 | 2019 | |
| Tandem Diabetes Care, INC. | $46.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $27.41 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $26.71 | 2019 | |
| Ascendis Pharma Endocrinology INC | $23.20 | 2025 | Yorvipath |
| Mallinckrodt Hospital Products INC. | $21.23 | 2025 | Acthar |
| Beta Bionics, INC. | $21.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Glaxosmithkline, LLC. | $20.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.34 | 2025 | |
| Vifor Pharma, INC. | $15.37 | 2025 | Veltassa |
| Ultragenyx Pharmaceutical INC. | $14.06 | 2019 | |
| Merck Sharp & Dohme LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cadena Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.